Olio Labs Unveils Sex-Based Differences in Obesity Drug Effects

Olio Labs has released a groundbreaking study that uncovers why women experience stronger side effects from GLP-1 drugs, such as Ozempic and Zepbound. Announced in a press release, the study reveals fundamental sex-based differences in how these weight loss medications interact with human biology.

The research highlights that women, who constitute 70% of GLP-1 drug users, show greater weight loss but suffer from 2.5 times higher rates of nausea and vomiting compared to men. This is attributed to nearly double the GLP-1 receptor expression in brain regions linked to nausea in female mice, a pattern that may be consistent across species.

Olio Labs' AI-powered Combination Design Engine (CoDE) was instrumental in mapping these biological systems, aiming to design personalized therapeutics. The study suggests that personalized dosing, adjusted according to menstrual cycle phases, could mitigate side effects and reduce discontinuation rates.

The findings were validated across species, including rats and mice, indicating that these sex-based differences are evolutionarily conserved. This research paves the way for more personalized treatment approaches, potentially improving outcomes for millions of patients.